Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5745056 | 0.94 | TLR7 (0.59) | TLR7TLR8 | |
| SCHEMBL5749419 | 0.94 | TLR7 (0.59) | TLR7TLR8 | |
| SCHEMBL5748529 | 0.94 | TLR7 (0.60) | TLR7TLR8 | |
| SCHEMBL13613807 | 0.91 | TLR7 (0.56) | TLR7TLR8 | |
| SCHEMBL5746646 | 0.91 | TLR7 (0.57) | TLR7TLR8 | |
| SCHEMBL6097027 | 0.90 | TLR7 (0.74) | TLR7TLR8 | |
| SCHEMBL5749608 | 0.90 | TLR7 (0.60) | TLR7TLR8 | |
| SCHEMBL14592846 | 0.90 | TLR7 (0.57) | TLR7TLR8 | |
| SCHEMBL5748138 | 0.90 | TLR7 (0.55) | TLR7TLR8 | |
| SCHEMBL14592757 | 0.89 | TLR7 (0.73) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1198232-B1 | UREA SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2006-08-23 | — | — | EP | claimed |
| US-6780873-B2 | FOR INDUCING CYTOKINE BIOSYNTHESIS IN ANIMALS, AND IN THE TREATMENT OF DISEASES, INCLUDING VIRAL AND NEOPLASTIC DISEASES | 3M INNOVATIVE PROPERTIES COMPANY | 2004-08-24 | — | — | US | claimed |
| US-20040014754-A1 | Urea substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-22 | — | — | US | claimed |
| EP-1198232-A4 | UREA SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2002-07-24 | — | — | EP | claimed |
| EP-1198232-A1 | UREA SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2002-04-24 | — | — | EP | claimed |
| WO-2000076518-A1 | UREA SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-12-21 | — | — | WO | claimed |
| US-7157453-B2 | Urea substituted imidazoquinolines | 3M INNOVATION PROPERTIES COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157453-B2 | Urea substituted imidazoquinolines | 3M INNOVATION PROPERTIES COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014754-A1 | Urea substituted imidazoquinolines | IFNG, EIF2AK2, IRF3 | TLR7 35/4885TLR8 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.